(NASDAQ: DYAI) Dyadic International's forecast annual revenue growth rate of 62.01% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.61%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.99%.
Dyadic International's revenue in 2026 is $3,086,721.On average, 5 Wall Street analysts forecast DYAI's revenue for 2026 to be $267,648,871, with the lowest DYAI revenue forecast at $192,517,957, and the highest DYAI revenue forecast at $341,937,870. On average, 5 Wall Street analysts forecast DYAI's revenue for 2027 to be $511,603,841, with the lowest DYAI revenue forecast at $275,025,653, and the highest DYAI revenue forecast at $758,645,834.
In 2028, DYAI is forecast to generate $449,823,298 in revenue, with the lowest revenue forecast at $432,183,168 and the highest revenue forecast at $463,053,395.